Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia

Biological Psychiatry

Volumn 46, Issue 12, 1999, Pages 1665-1671

  Lin, Xian Hao ^a   Kitamura, Noboru ^b   Hashimoto, Takeshi ^a   Shirakawa, Osamu ^a   Maeda, Kiyoshi ^a  

^a KOBE UNIVERSITY   (Japan)

^b Shinko Hospital   (Japan)

Author keywords

Human brain; Immunoblotting; Phosphoinositide specific phospholipase C (PLC); Prefrontal cortex; Schizophrenia; Superior temporal cortex

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OXYPERTINE; PERICIAZINE; PHOSPHATIDYLINOSITIDE; PHOSPHOLIPASE C; THIORIDAZINE; TIOTIXENE; TRIMIPRAMINE;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOREACTIVITY; MALE; NEUROTRANSMISSION; PHOSPHOINOSITIDE METABOLISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; TEMPORAL CORTEX;

AMYGDALA; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEUS ACCUMBENS; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C; PREFRONTAL CORTEX; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 0033407593     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00036-0     Document Type: Article

References (35)

1. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997): The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9:1-17.
2. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE, Jones EG (1993): Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178-187.
3. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press.
4. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE (1990): Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147: 1457-1462.
5. Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979): Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36:927-934.
6. Berridge MJ, Irvine RF (1984): Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 312:315-321.
7. Berridge MJ (1993): Inositol trisphosphate and calcium signaling. Nature 361:315-325.
8. Carpenter WT Jr, Buchanan RW (1994): Medical progress: schizophrenia. N Eng J Med 330:681-690.
9. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA (1985): Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329-332.
10. Cockcroft S, Thomas GMH (1992): Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. Biochem J 288:1-14.
11. Das I, Essali MA, de Belleroche J, Hirsh SR (1992): Inositol phospholipid turnover in platelets of schizophrenic patients. Prostaglandins Leukotrienes Essent Fatty Acids 46:65-66.
12. 2/1c antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 163:451-455.
13. 2 dopamine receptors in the temporal lobe in schizophrenia. Arch Gen Psychiatry 54:649-658.
14. Gurevich EV, Joyce JN (1997): Alteration in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 42:529-545.
15. Hepler JR, Kozasa T, Smrcka AV, Simon MI, Rhee SG, Sternweis PC, et al (1993): Purification from Sf9 cells and characterization of recombinant Gqα and G11α. J Biol Chem 268:14367-14375.
16. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, et al (1998): Selective increase in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J Neurochem 70:763-771.
17. 3H]PtdIns hydrolysis in postmortem human brain membranes is mediated by the G-protein Gq/11 and phospholipase C-β. Biochemistry 304:655-659.
18. Kaiya H, Nishida A, Imai A, Nakashima S, Nozawa Y (1989): Accumulation of diacyl-glycerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis? Biol Psychiatry 26:669-676.
19. Kapur S, Remington G (1996): Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476.
20. Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
21. Lucas JJ, Hen R (1995): New players in the 5-HT receptor field: genes and knockouts. Trends Pharmacol Sci. 16:246-252.
22. 1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30:349-356.
23. 3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease. Brain Res 377:186-189.
24. Nishizuka Y (1988): The molecular heterogeneity of protein kinase C and its implication for cellular regulation. Nature 334:661-665.
25. Petty RG, Barta PE, Pearlson GD, McGilchrist IK, Lewis RW, Tien AY, et al (1995): Reversal of asymmetry of the planum temporale in schizophrenia. Am J Psychiatry 152:715-721.
26. Pin JP, Duvoisin R (1995): Review: neurotransmitter receptors. I. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
27. Rhee SG, Choi KD (1992): Regulation of inositol phospholipid-specific phospholipase C isozymes. J Biol Chem 267:12393-12396.
28. Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U (1997): Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 349:1735-1739.
29. Smrcka AV, Sternweis PC (1993): Regulation of purified subtypes of phosphatidylinositol-specific phospholipase C β by G protein α and β-γ subunits. J Biol Chem 268:9667-9674.
30. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M, Wible CG, et al (1992): Abnormalities of the left temporal lobe and thought disorder in schizophrenia: a quantitative magnetic resonance imaging study. N Engl J Med 327:604-612.
31. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA (1991): Muscarinic cholinergic hyperactivity in schizophrenia relationship to positive and negative symptoms. Schizophr Res 4:23-30.
32. Wallace MA, Claro E (1993): Transmembrane signaling through phospholipase C in human cortical membranes. Neurochem Res 18:139-145.
33. Yang CQ, Kitamura N, Nishino N, Shirakawa O, Nakai H (1998): Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol Psychiatry 43:12-19.
34. Yao JK, Yasaei P, van Kammen DP (1992): Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins Leukotrienes Essent Fatty Acids 46:39-46.
35. Yu P-Y, Asico LD, Eisner GM, Jose PA (1995): Differential regulation of renal phospholipase C isoforms by catecholamines. J Clin Invest 95:304-308.